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In the treatment of renal adenocarcinoma, radiation therapy 
alone is insufficient. Preoperative radiation increases the 
resectability rate and delays metastasis, but overa// improve-
ment in survival is tentative. Postoperative radiation has not 
been of proven benefit. While palliation may be achieved, 
relatively high doses of radiation are required. 
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The relative radioresistance of renal adenocarcinoma 
compared to the sensitivity of the surrounding normal 
tissues makes definitive radiation alone inappropriate for 
curative therapy. As an adjuvant to definitive surgery, 
radiation remains controversial, although some randomized 
clinical trials are presently active. While palliation may be 
achieved, relatively high doses of radiation are necessary 
Preoperative Radiation 
As early as 1935, reports'''^ in the literature indicated that 
preoperat ive radiat ion could convert renal adenocar-
cinomas from nonresectable to resectable. In addftion to 
conversion, some theoretical advantages to preoperative 
radiation include: 
a) Reduction in viability of tumor cells, thereby reducing 
the incidence of distant metastasis caused by the 
release of cells during surgical manipulation. 
b) Reduction of microscopic peripheral extensions into 
pericapsular and perirenal tissue, thereby reducingthe 
risk of transecting viable tumor. 
c) Reduction in the incidence of local recurrence by 
directly affecting surrounding normal tissues to make 
them less susceptible to implantation. 
d) Sterilization of microdeposits in lymph nodes. 
Several reported series '^^  have indicated no survival advan-
tage with preoperative radiation. 
Werf-Messing^ reported the first large, randomized series 
from the Netherlands. Although there was no survival 
advantage, she observed that the unresectability rate de-
creased from 38% to 20% for patients with pericapsular 
extension and preoperative irradiation. When venous or 
lymphatic invasion occurred, 78% of patients could be 
completely resected ifthey had received preoperative radia-
tion, but only 48% could be resected if this treatment had 
not been given. Further, itwas noted that metastases did not 
develop as rapidly in patients whose tumor was completely 
resected. 
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Inthe United States, a national renal cell cooperative trial is 
in progress. A higher dose of radiation was chosen with 
complex techniques of administration being employed to 
limit the dose to vital structures. Preliminary analysis of the 
data by Rubin et al^ indicated no advantage to patients with 
stage I disease. In the preoperatively irradiated group, 
patientswith stage II disease showed a 15-20% improve-
ment in two-year survival. As in the Netherlands' study, 
patients who had complete tumor resection took longer to 
manifest distant metastasis. Also, a much higher percentage 
of patients with preoperative radiation were completely 
resected. A major problem Rubin, et al* noted was the 
extreme difficulty in delivering the required tumor dose to 
the lymph node-bearing region. Therefore, they recom-
mended surgical resection of regional nodes and venous 
tumor thrombus, if present, because it was impossible to 
radiate these areas without exceeding normal tissue toler-
ance. More patients and longer follow-up are necessary. 
Postoperative Radiation 
In 1951, Riches, et reported on a series of 1,746 cases 
studied by the British Association of Urologic Surgeons. 
Flocks and Kadesky^ and Riches'" suggested the following 
indications for postoperative radiation: perinephric tumor 
invasion, incomplete resection, and regional lymph node 
metastasis. On an individual basis, surgical spillage of 
tumor into the renal bed has also been considered as an 
indication. 
While the former studies suggest a 10-15% improvement in 
five-year survival, randomized clinical trials reported by 
Peeling et a l " and Finney'^ indicated no significant dif-
ference, or even a slightly worse result, with postoperative 
radiation. Finney^^ suggested that the lessened survival in 
the postoperative radiation group was due to radiation 
complications, primarily to radiation hepatitis in right-sided 
lesions. He also found no difference in the incidence of 
local recurrence of distant metastasis. Of prime importance 
were known prognostic factors such as renal vein invasion 
and capsular extension. 
Palliative Radiation 
The relief of symptoms dueto local tumor mass or metastasis 
can be achieved in a large proportion of patients. Our 
experience is similar to that reported by Vaeth''" in that 
relatively high doses in the range of 4-5,000 rads in four to 
five weeks are necessary. In the palliative category are such 
problems as bone pain, brain metastasis, and bronchial 
obstruction. We have also treated two patients with tumor 
thrombus extending up the inferior vena cava into the right 
atrium of the heart. While we did not note any significant 
improvement, Malkin,^* in a similar case, docmented 
marked regression which made the patient resectable. 
Summary 
Both pre- and postoperative radiation are local measures in 
renal adenocarcinoma. Preoperative radiation increases 
the resectability rate and delays metastasis. However, any 
overall improvement in survival is tentative with more study 
needed. Postoperative radiation has not been of demon-
strated benefit. Improvement in controlling distant spread is 
required before any additional benefft from radiation used 
for local control can be demonstrated. High doses of 
radiation are required to gain maximum benefft both as a 
surgical adjuvant and for palliation. 
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